BED, biologically effective dose; BID, twice-a-day; BMI, body-mass index; BT, brachytherapy; Brachytherapy; CT, computerized tomography; CTCAE, common terminology criteria for adverse events; CTV, clinical target volume; Cervical cancer; EBRT, external beam radiotherapy; EMBRACE, image guided intensity modulated External beam radiochemotherapy and MRI based Adaptative BRAchytherapy in locally advanced CErvical cancer; EQD2Gy, equivalent dose at 2 Gy; ESTRO, European Society for Radiotherapy and Oncology; FIGO, International Federation of Gynecology and Obstetrics; Fractionation scheme; GEC, groupe européen de curiethérapie; GTV, gross tumor volume; HDR, high-dose-rate; HIV, human immunodeficiency virus; HR, high-risk; High-dose-rate; ICRU, International Commission on Radiation Units and measurements; IGABT, image-guided adaptative brachytherapy; IMRT, intensity modulated radiotherapy; IR, intermediate-risk; LACC, locally advanced cervical cancer; LDR, low-dose-rate; LFS, local recurrence-free survival; LQ, linear quadratic; MFS, metastatic recurrence-free survival; MFU, median follow up; MRI, magnetic resonance imaging; NA, not available; NCI, national cancer institute; NFS, nodal recurrence-free survival; OAR, organs at risk; OS, overall survival; OTT, overall treatment time; PDR, pulsed-dose-rate; PET, positron emission tomography; PFS, progression-free survival; PTV, planning target volume; RCT, radio-chemotherapy; SCC, squamous cell cancer; SEER, surveillance, epidemiology and end results; pt, patient; pts, patients